Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by pericles1on Apr 10, 2012 12:01pm

359 Views

Post# 19776005

Childrens's trial

The NCI is running this trial, they have increased the sites from 17 to 20. It's kind of funny we are way past the completion date yet they don't seem to update it. Noticed the increase in sites because of Children's Hospital of Milwaukee which is closest to me. I learned a long time ago that the NCI runs at their own schedule which has nothing to do with what's posted!

https://cancer.gov/clinicaltrials/search/view?cdrid=688938&version=healthprofessional